Peer-reviewed veterinary case report
Dogs with T-cell lymphoma treated with asparaginase and MOPP
By Brodsky, E M et al.·Published in Journal of veterinary internal medicine·2009·Veterinary Oncology and Hematology Center, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Asparaginase and MOPP treatment of dogs with lymphoma.
- Species:
- dog
Plain-English summary
Fifty dogs with T-cell lymphoma or hypercalcemic lymphoma were treated with a combination of L-asparaginase and MOPP chemotherapy, which includes mechlorethamine, vincristine, prednisone, and procarbazine. Most dogs responded well to the treatment, with a 98% overall response rate—78% achieving complete remission. On average, dogs lived about 270 days after starting treatment, with some surviving up to 939 days. While some dogs faced complications that required hospitalization, the L-Asp/MOPP treatment showed promise for longer survival compared to traditional chemotherapy methods.
People also search for: dog lymphoma treatment · T-cell lymphoma in dogs · chemotherapy side effects in dogs
Abstract
BACKGROUND: Dogs with multicentric lymphoma are treated with various cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy protocols with variable success. OBJECTIVES: To describe the progression-free survival (PFS) time and overall survival time (OST) of dogs with T-cell lymphoma or hypercalcemic lymphoma treated with L-asparaginase and mechlorethamine, vincristine, prednisone, procarbazine (MOPP). ANIMALS: Fifty dogs with T-cell lymphoma, hypercalcemic lymphoma, or both treated at 3 referral veterinary hospitals. METHODS: Retrospective study. Case were selected based on histologic or cytologic diagnosis of lymphoma; presence of the T-cell phenotype, presence of hypercalcemia or both; and absence of previous chemotherapy. The T-cell phenotype was determined by flow cytometry, immunocytochemistry, immunohistochemistry, or polymerase chain reaction of antigen receptor rearrangement. RESULTS: The overall response rate was 98% (78% complete response, 20% partial response). The median PFS for the entire study population was 189 days with 25% PFS at 939 days. The median OST for the entire study population was 270 days with 25% surviving 939 days. Twenty percent of the dogs required hospitalization for treatment related complications. CONCLUSIONS AND CLINICAL IMPORTANCE: L-Asp/MOPP chemotherapy might result in longer PFS and OST for dogs with multicentric T-cell lymphoma, dogs with hypercalcemic lymphoma or both, than achieved with CHOP.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19645842/